JGC
DERM icon

J. Goldman & Co’s Journey Medical DERM Stock Holding History

J. Goldman & Co’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.35M Sell
500,188
-298,178
-37% -$2.31M 0.07% 297
2025
Q4 		$6.16M Buy
+798,366
New +$6.26M 0.16% 170

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return

J. Goldman & Co's DERM Position: Q1 2026 in Review

J. Goldman & Co reduced its Journey Medical (DERM) stake by 37% in Q1 2026, selling an estimated $2.31M and leaving 500,188 shares worth $2.35M. The position accounts for 0.07% of the portfolio, ranked #297.

J. Goldman & Co first reported a position in DERM in Q4 2025 and has held it in 2 quarters since. The position peaked at $6.16M in Q4 2025. 71 funds tracked by Wall St. Rank hold DERM as of Q1 2026.

  • J. Goldman & Co held 500,188 shares of Journey Medical worth $2.35M as of Q1 2026.
  • J. Goldman & Co sold 298,178 Journey Medical shares in Q1 2026, an estimated $2.31M.
  • Journey Medical made up 0.07% of J. Goldman & Co's portfolio in Q1 2026, its #297 holding.
  • J. Goldman & Co first reported a position in Journey Medical in Q4 2025 and has held it in 2 quarters since.
  • J. Goldman & Co's Journey Medical position peaked at $6.16M in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.